AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05563181 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control bar code label
Description: Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
Study NCT05563181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control bar code label
Description: Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
Study NCT05563181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning label
Description: Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages
Study NCT05678140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization
Description: soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
Study NCT06463548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride liposome injection
Description: Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
Study NCT06463548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
Study NCT06463548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
Study NCT05016869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib plus capecitabine
Description: Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W
Study NCT04958421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCSO Impulse System
Description: After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
Study NCT06376266 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplements
Description: a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
Study NCT06376266 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: nutritional supplements
Description: a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
Study NCT04673136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI-GENIUS Medtronic
Description: Colonoscopy assisted by GI-GENIUS device
Study NCT04673136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Standard colonoscopy
Study NCT05731466 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CardioMems HF System
Description: 1. Implantation CardioMems device.~2. Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements.
Study NCT05563181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational campaign poster about added-sugar warning labels
Description: Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
Study NCT04844021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: EHR-based nudge
Study NCT04844021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge+
Description: EHR-based nudge plus facilitation
Study NCT04916496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-based lifestyle counselling programme
Description: The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change.
Study NCT04916496 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy lifestyle talk
Description: The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change.
Study NCT04880720 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling - 10mL
Study NCT06023862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Intravenous (IV) infusion
Study NCT06023862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous (IV) infusion
Study NCT06023862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Intravenous (IV) infusion
Study NCT06023862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous (IV) infusion
Study NCT06023862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous (IV) infusion
Study NCT06023862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Intravenous (IV) infusion
Study NCT05678140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional physical therapy
Description: Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
Study NCT05678140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
Study NCT05548426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B, Linezolid 10d
Description: Oral Linezolid 600mg, taken twice a day for 10 days
Study NCT05548426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A, Penicillin
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Study NCT05471414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-food, Plant-Based Diet
Description: Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.
Study NCT05471414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Nutritional Counseling
Description: All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls.
Study NCT05813899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 heat-treated
Description: PS23 heat-treated, 2 caps daily use
Study NCT05813899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PS23 heat-treated
Description: PS23 heat-treated, 2 caps daily use
Study NCT06048991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermographic assessment
Description: Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
Study NCT06552325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Narrative Therapy
Description: The proposed single session narrative therapy intervention has been widely implemented in walk-in therapy clinics in Ontario Province, Canada. In these clinics, 60-minute psychotherapy sessions, informed by narrative therapy, are available on a walk-in basis. The therapist collaborates with a patient to co-develop a useful and meaningful focus for the session and then engages the patient in conversation that is respectful but shifts their way of thinking about the presenting problem. The therapist highlights and documents the patient's values and skills and works with the patient to create an action plan. If the therapist identifies additional treatment needs, the patient is offered an external referral to specialty mental health services.
Study NCT05457127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP)
Description: If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise.
Study NCT04077151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Demonstration Project
Description: In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
Study NCT05667454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic 0.05%
Description: Atropine 0.05% sulphate ophthalmic solution
Study NCT05667454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic 0.5%
Description: Atropine 0.5% sulphate ophthalmic solution
Study NCT06377111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-PAN
Description: C-PAN is an essential nutrient as it is required for the synthesis of CoA, a key cofactor in the tricarboxylic acid cycle and fatty acid metabolism, as well as for the synthesis of acyl carrier protein. Pantothenate appears to be safe in humans with studies describing the administration of doses up to 10 grams per day over prolonged periods of time; hence, no upper limit for tolerability has been established. In this study, oral supplement consisting of 2000 mg daily of C-PAN will be administered to a single cohort of patients.
Study NCT06377111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Nivolumab 1 mg/kg every 3 weeks for up to 4 cycles (upon patient´s tolerability) followed by maintenance Nivolumab 3 mg/kg (or fixed dose 240 mg) every 2 weeks or Nivolumab 6 mg/kg (or fixed dose 480 mg) every 4 weeks.
Study NCT06377111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein CTLA-4 on immune cells called T cells. Ipilimumab 3 mg/kg every 3 weeks for up to 4 cycles.
Study NCT04311450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) counseling
Description: This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
Study NCT06058091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RY_SW01 cell injection
Description: Administer basic treatment with an injection of RY_SW01 cell solution
Study NCT06058091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basic treatment
Description: Basic treatment for SSc
Study NCT06058091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Basic treatment for SSc
Study NCT04179617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% nicotine content JUUL pod
Description: JUUL pods that contain 5% nicotine
Study NCT04179617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% nicotine content JUUL pod
Description: JUUL pods that contain 3% nicotine
Study NCT05699200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterial Tonometry
Description: We will measure arterial stiffness using arterial tonometry.
Study NCT05699200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiogram
Description: We will collect limited ultrasound images of the heart.
Study NCT05407090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic supplementation
Description: Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
Study NCT05407090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants enrolled in the placebo group will receive a placebo instead of probiotics.
Study NCT06187116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist consultation
Description: The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
Study NCT06187116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic surgeon consultation
Description: The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
Study NCT05699200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Carotid Ultrasounds
Description: We will perform ultrasound imaging of the carotid artery.
Study NCT05412394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Liquid, 5mg/kg per week, for one year
Study NCT05637723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: schroth exercise
Description: The schroth exercise program will be given 3 days a week for 6 weeks.
Study NCT05637723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional scoliosis exercises
Description: The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
Study NCT05087641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IAB System
Description: Bronchoscopic implantation of one or multiple IABs
Study NCT06395428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Intramuscular injection of drug
Study NCT06395428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: Intramuscular injection of drug
Study NCT06147531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delayed Cold-Stored Buffy Coat Platelets
Description: To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
Study NCT05699200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elastography
Description: We will measure the elastic properties of the arteries using elastography.
Study NCT06147531 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Room Temperature Buffy Coat Platelets
Description: Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
Study NCT05699200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ankle-Brachial Index
Description: We will measure the ankle-brachial index to assess peripheral artery blood flow.
Study NCT05699200 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microneurography with sympathoexcitatory maneuvers
Description: We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
Study NCT06170788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: IV infusion
Study NCT06341335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: iv, q3w
Study NCT06170788 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study NCT06170788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT06341335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pulocimab
Description: iv, q3w
Study NCT06341335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: iv, q3w